Getting New Pain Drugs to Market: 3 Challenges

September 21, 2021

Each September, pain advocates and specialists raise awareness about issues facing the millions of people living with chronic pain. One of the most pressing? The lack of treatments available to alleviate suffering. In this blog, we look at three top challenges of getting new pain drugs to market—and offer a potential solution.

Can Daily Self-Assessment Induce A Learning Effect Mitigating Pain Evaluation Error In Randomized Clinical Trials?

April 30, 2021

Scientific Poster presented on April 2021 at the Osteoarthritis Research Society International Meeting. Purpose Questionnaires assessing  patients’ pain level represent the majority of  efficacy endpoints in osteoarthritis (OA) randomized clinical trials (RCTs).  The intrinsic subjectivity of pain may render the evaluation of these questionnaires difficult. In turn, this could explain the high variability observed in the treatment response

“Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm” published in Pain.

November 18, 2020

The journal article “Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm”, has been published ahead of print in the journal Pain. This article was authored by Didier Bouhassira, MD, Director of Research at the National Institute for Health and Medical Research (INSERM) in France and member of Tools4Patient’s scientific advisory board, and was co-authored by Tools4Patient scientists Samuel Branders PhD, Alvaro Pereira PhD and Dominique Demolle, PhD.

The Opioid Crisis in the US: Fueling the Next Wave of Drug Development for Chronic Pain

February 18, 2020

While the opioid crisis may be creating opportunity for development of novel therapies to treat chronic pain, drug development in this area has historically struggled. According to a BIO report released in 2018, only two novel NCEs were approved for pain indications from 2007-2017 while other analgesia approvals during this period were reformulations of existing compounds or drugs with approval history prior to 2007.